|Articles|September 25, 2015
Lecia V. Sequist on Side Effects From Agents for Resistant Lung Cancer
Author(s)Lecia V. Sequist
Lecia V. Sequist, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291).
Advertisement
Lecia V. Sequist, associate professor of medicine, Massachusetts General Hospital, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291), two agents specific to acquired T790M mutations in EGFR-positive non-small cell lung cancer (NSCLC).
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Living With Leukemia Chester Freeman Embraces Wabi-Sabi
2
Fertility Preservation During Breast Cancer: ‘I Would Do It All Again’
3
Becoming Cancer-Aware: How My Diagnosis Changed the Way My Family Sees Everyday Products
4
What Are My Options for Liver Cancer Treatment?
5
